Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

232
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
232
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

505
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
505
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

234
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
234
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

371
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
371
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

725
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
725

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion.

Diabetologia·2026
Same author

Acute and 14-day effects of tiotropium/olodaterol on cardiopulmonary function in COPD.

ERJ open research·2026
Same author

A synaptoid connectome differentiates tanycytic subpopulations and underlies neuroglial communication and neuroendocrine regulation.

Nature communications·2026
Same author

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
Same author

Postmortem MRI reveals distinct structural features in sudden unexpected death in epilepsy.

Epilepsia open·2026
Same author

Thyrotropin-releasing hormone neurons of different hypothalamic nuclei increase energy expenditure.

Nature communications·2026

Related Experiment Video

Updated: Aug 4, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.7K

In atrial fibrillation epilepsy risk differs between oral anticoagulants: active comparator, nested case-control

Katharina Platzbecker1, Helge Müller-Fielitz2, Ronja Foraita1

  • 1Leibniz Institute for Prevention Research and Epidemiology-BIPS, Achterstraße 30, 28359 Bremen, Germany.

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
|April 4, 2023
PubMed
Summary

Direct oral anticoagulants (DOACs) for atrial fibrillation (AF) showed a higher epilepsy risk than phenprocoumon (PPC). This suggests DOACs may increase epilepsy risk in AF patients, potentially due to covert brain infarction.

Keywords:
AnticoagulationAtrial fibrillationDirect oral anticoagulantsEpilepsySilent strokeVitamin K antagonist

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Reduced Procedure Time and Variability with Active Esophageal Cooling During Radiofrequency Ablation for Atrial Fibrillation
04:58

Reduced Procedure Time and Variability with Active Esophageal Cooling During Radiofrequency Ablation for Atrial Fibrillation

Published on: August 25, 2022

2.3K

Related Experiment Videos

Last Updated: Aug 4, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.7K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Reduced Procedure Time and Variability with Active Esophageal Cooling During Radiofrequency Ablation for Atrial Fibrillation
04:58

Reduced Procedure Time and Variability with Active Esophageal Cooling During Radiofrequency Ablation for Atrial Fibrillation

Published on: August 25, 2022

2.3K

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacoepidemiology

Background:

  • Atrial fibrillation (AF) is a known risk factor for cerebrovascular events, including brain infarction.
  • Brain infarction can lead to the development of epilepsy.
  • The comparative risk of epilepsy associated with different anticoagulant therapies in AF patients remains an important clinical question.

Purpose of the Study:

  • To investigate the association between direct oral anticoagulants (DOACs) and epilepsy risk in patients with atrial fibrillation (AF).
  • To compare the risk of epilepsy in AF patients treated with DOACs versus vitamin K antagonist phenprocoumon (PPC).

Main Methods:

  • An active comparator, nested case-control study was conducted using German health insurance claims data (25 million individuals, 2004-2017).
  • 227,707 AF patients initiating treatment with DOACs or PPC were analyzed.
  • 1,828 cases of epilepsy were matched with 19,084 controls; analyses considered baseline CHA2DS2-VASc scores and history of stroke.

Main Results:

  • Patients with AF treated with DOACs exhibited a significantly higher risk of epilepsy (OR 1.39, 95% CI [1.24; 1.55]) compared to those treated with PPC.
  • This increased risk persisted even after excluding patients with prior ischemic stroke.
  • In a separate cohort of patients with venous thromboembolism, the epilepsy risk associated with DOACs was less elevated (aOR 1.15, 95% CI [0.98; 1.34]).

Conclusions:

  • Treatment with DOACs for atrial fibrillation is associated with an increased risk of epilepsy compared to phenprocoumon.
  • The findings suggest a potential link between DOAC therapy and epilepsy development in AF patients.
  • Covert brain infarction is hypothesized as a potential mechanism underlying the observed elevated epilepsy risk with DOACs.